(Q42450444)

English

Distinguishing Atrophy and High-Grade Prostatic Intraepithelial Neoplasia From Prostatic Adenocarcinoma With and Without Previous Adjuvant Hormone Therapy With the Aid of Cytokeratin 5/6

scientific article published on September 1, 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

Distinguishing Atrophy and High-Grade Prostatic Intraepithelial Neoplasia From Prostatic Adenocarcinoma With and Without Previous Adjuvant Hormone Therapy With the Aid of Cytokeratin 5/6 (English)

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

high-grade prostatic intraepithelial neoplasia

0 references

1 reference

based on heuristic

inferred from title

David G. Bostwick

2

object named as

David G Bostwick

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

author name string

Junqi Qian

4

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

Neil A. Abrahams

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14502799

12 March 2024

Adrian H. Ormsby

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14502799

12 March 2024

Jennifer A. Brainard

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14502799

12 March 2024

language of work or name

1 reference

American Journal of Clinical Pathology

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

American Journal of Clinical Pathology

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

120

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

368-376

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies

1

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

2

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results

3

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

4

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Clinical and Pathobiological Effects of Neoadjuvant Total Androgen Ablation Therapy on Clinically Localized Prostatic Adenocarcinoma

7

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma

9

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.

10

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy

11

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Differential diagnosis of glandular proliferations in the prostate. A conventional and immunohistochemical approach

12

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation.

13

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma

15

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Efficacy of restaining prostate needle biopsies with high-molecular weight cytokeratin

16

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer

17

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells

18

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.

19

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody

20

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma.

21

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma

23

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process

24

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens

25

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Adenocarcinoma of the prostate with atrophic features

26

1 reference

10.1309/3YNLXCR33817JLTR

https://api.crossref.org/works/10.1309/3YNLXCR33817JLTR

12 March 2024

Identifiers

10.1309/3YNLXCR33817JLTR

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42450444&oldid=2100524838"